Intellia exits hemophilia B pact with Regeneron; Sangamo targets $24M raise

2024-03-22

基因疗法引进/卖出

Plus, news about OKYO Pharma: Intellia departs Regeneron deal: The CRISPR biotech disclosed Friday that it had opted out of a partnership with Regeneron to develop a factor IX gene editing therapy. The partners had penned the deal in 2020, which made Intellia responsible for 35% of development costs in exchange for 35% of profits. Regeneron in February announced that the FDA had cleared the gene insertion program to be tested in a clinical trial for people with hemophilia B, which is slated to begin in mid-2024. Regeneron can still develop a CRISPR-based factor IX therapy under an earlier licensing agreement, the biotech noted in its SEC filing, making Intellia eligible for up to $320 million in future milestones. Intellia still has 35% stake in a factor XIII insertion program for hemophilia A.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构